Related Experiment Video
Updated: Sep 26, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Castleman disease (CD) is a rare blood disorder. This study outlines symptoms and presents international consensus criteria for diagnosing and treating idiopathic multicentric Castleman disease (iMCD).
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Castleman disease (CD) encompasses diverse hematologic disorders characterized by lymph node enlargement.
- CD presents as unicentric (UCD) or multicentric (MCD) forms.
- MCD can be associated with human herpesvirus-8 (HHV-8) or be HHV-8-negative/idiopathic (iMCD).
Purpose of the Study:
- To report on the symptoms of idiopathic multicentric Castleman disease (iMCD).
- To present the international consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
- To outline international evidence-based treatment guidelines for iMCD.
Main Methods:
- Literature review and expert consensus.
- Analysis of diagnostic and treatment data for iMCD.
- Development of evidence-based guidelines.
Main Results:
- iMCD presents with a range of symptoms and can have poor outcomes.
- International consensus criteria for diagnosing iMCD have been established.
- Evidence-based treatment guidelines for iMCD are now available.
Conclusions:
- Accurate diagnosis and standardized treatment are crucial for managing iMCD.
- The established criteria and guidelines aim to improve patient outcomes in iMCD.
- Further research may refine understanding and treatment of this rare disorder.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Chronic Kidney Disease III: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy